Summit Therapeutics Gets a Buy Rating from Canaccord Genuity


In a report released today, Arlinda Lee from Canaccord Genuity maintained a Buy rating on Summit Therapeutics (NASDAQ: SMMT), with a price target of $3. The company’s shares opened today at $2.45, close to its 52-week low of $2.17.

According to TipRanks.com, Lee is a 2-star analyst with an average return of 0.5% and a 42.4% success rate. Lee covers the Healthcare sector, focusing on stocks such as Eloxx Pharmaceuticals Inc, Karyopharm Therapeutics, and Aquinox Pharmaceuticals.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Summit Therapeutics with a $8 average price target, representing a 226.5% upside. In a report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $3 price target.

.

See today’s analyst top recommended stocks >>

The company has a one-year high of $16.86 and a one-year low of $2.17. Currently, Summit Therapeutics has an average volume of 80.55K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Summit Therapeutics Plc is a holding company, which engages in the discovery, development, and commercialization of novel medicines. It focuses on the genetic disease duchenne muscular dystrophy, and the infectious disease clostridium difficile infection.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts